Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.36 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.36 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.36 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.36 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.36 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.35 |
| ▸ | ANPEP | P15144 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17919549 | 0.98 | MEN1 (0.44) | CYP2C9CYP2C19TSHRMAPK1MEN1 | |
| SCHEMBL18160820 | 0.85 | CYP2C9 (0.50) | CYP2C9CYP2C19TSHRMAPK1TDP1 | |
| SCHEMBL29173976 | 0.83 | TSHR (0.41) | CYP2C9CYP2C19TSHRMAPTTDP1 | |
| SCHEMBL720627 | 0.82 | TSHR (0.62) | CYP2C19TSHRMAPK1MEN1KMT2A | |
| SCHEMBL25379173 | 0.82 | TDP1 (0.50) | CYP2C9CYP2C19TSHRMAPK1MEN1 | |
| SCHEMBL5932834 | 0.80 | CYP2C9 (0.42) | CYP2C9CYP2C19TSHRMAPTTDP1 | |
| SCHEMBL21001064 | 0.80 | KDM4E (0.37) | CYP2C19TSHRMAPK1MEN1KMT2A | |
| SCHEMBL7077220 | 0.79 | MEN1 (0.65) | TSHRMAPK1MEN1KMT2AMAPT | |
| SCHEMBL15965457 | 0.79 | MEN1 (0.65) | TSHRMAPK1MEN1KMT2AMAPT | |
| SCHEMBL31584385 | 0.79 | MEN1 (0.65) | TSHRMAPK1MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040009938-A1 | Methods of enhancing renal uptake of oligonucleotides | ISIS PHARMACEUTICAL INC. | 2004-01-15 | — | — | US | disclosed |
| US-6600032-B1 | Compound for use in the treatment of viral, protozoan and parasitic infections | ISIS PHARMACEUTICALS, INC. | 2003-07-29 | — | — | US | disclosed |
| EP-1102787-A1 | 2'-O-AMINOETHYLOXYETHYL-MODIFIED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 2001-05-30 | — | — | EP | disclosed |
| WO-2000008044-A1 | 2'-O-AMINOETHYLOXYETHYL-MODIFIED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 2000-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009938-A1 | Methods of enhancing renal uptake of oligonucleotides | NUDT1, SLC29A2, DUT | CYP2C9 3349/4885CYP2C19 3611/4885TSHR 1259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.